Earnings Feed
Start Free
Xeris Biopharma Holdings, Inc.·4

Jun 5, 6:29 PM ET

PERSKY MARLA 4

Research Summary

AI-generated summary

Updated

Xeris (XERS) Director Marla Persky Sells 15,500 Shares & Receives Awards

What Happened

  • Marla Persky, a director of Xeris Biopharma (XERS), sold 15,500 shares in an open-market transaction on June 3, 2026 for a weighted average price of $5.90, generating proceeds of $91,433.
  • On June 4, 2026 she was reported as receiving two awards: 24,193 restricted stock units (RSUs) (acquired at $0) and a derivative award of 32,996 shares reported at $6.15 (listed value $202,925). The derivative award is a stock‑option style grant per the filing.

Key Details

  • Transaction dates: sale on 2026-06-03; awards reported 2026-06-04. Form filed 2026-06-05 (timely).
  • Sale details: weighted average sale price $5.90; individual sale prices ranged $5.810–$5.960. Sale was made under a Rule 10b5-1 trading plan adopted June 12, 2025.
  • RSUs (24,193): granted under the 2018 Plan; represent contingent rights to one share each and vest in full on the earlier of June 4, 2026 or the company’s next annual meeting, subject to continued service.
  • Options/derivative (32,996): granted under the Plan and vest in full on the earlier of June 4, 2026 or the company’s next annual meeting, subject to continued service. Filing reports these at $6.15 ($202,925).
  • Beneficial ownership: the reporting person disclaims beneficial ownership except to the extent of pecuniary interest; the Form does not list total shares owned after these transactions.
  • Filing timeliness: included in a Form 4 filed June 5, 2026 — not marked late.

Context

  • The sale was executed under a pre-established 10b5-1 plan (routine trading arrangement), which often indicates the sale was pre-planned rather than a spontaneous vote of confidence or concern.
  • RSU and option grants are awards that typically vest over service/vesting dates; they do not necessarily indicate immediate buying or selling of shares.
  • No indication in this filing that options were exercised for immediate sale (i.e., not a cashless exercise reported here).

If you want, I can check prior Form 4s for Persky to show how these grants fit into her historical compensation or ownership.